OssDsign

OssDsign EBIT per Share

The EBIT per Share of OssDsign (OSSD.ST) as of Nov 3, 2026 is -0.44 SEK. In the previous year, EBIT per Share was -0.51 SEK — a change of -13.88% (higher).

EBIT per Share

-0.44SEK

YoY

-13.88%

Last updated:

EBIT per Share of OssDsign is 2025 -0.44 SEK. EBIT per Share of OssDsign was 2024 -0.51 SEK. It decreases by -13.88% higher compared to the previous year.

The OssDsign EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2022
-1.42 SEK
Jan 1, 2023
-1.02 SEK
Jan 1, 2024
-0.51 SEK
Jan 1, 2025
-0.44 SEK
Jan 1, 2026 (e)
-0.42 SEK
Jan 1, 2027 (e)
-0.35 SEK
Jan 1, 2028 (e)
-0.16 SEK
Jan 1, 2029 (e)
-0.23 SEK
The OssDsign EBIT per Share history
YEAREBIT per ShareYoY
est-0.23SEK+45.72%
est-0.16SEK-56.12%
est-0.35SEK-15.15%
est-0.42SEK-4.02%
-0.44SEK-13.88%
-0.51SEK-50.61%
-1.02SEK-27.64%
-1.42SEK-5.45%
-1.50SEK-59.76%
-3.72SEK+5.68%
-3.52SEK+64.86%
-2.14SEK+471.12%
-0.37SEK+7.73%
-0.35SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OssDsign Stock analysis

What does OssDsign do? OssDsign AB develops and sells medical technology products, focusing on implantable solutions for bone healing, particularly in skull surgery. Its primary product, Craniomosaic, is an implant for skull defect repair (cranioplasty), while it also develops bioceramic implants for facial bone augmentation. The company uses proprietary bioceramic technologies that integrate with tissues and support bone ingrowth. Customers include neurosurgeons, craniofacial, and maxillofacial surgeons who purchase these products for surgical procedures. The company generates revenue through the development and sales of its medical technology products, specifically Craniomosaic and bioceramic implants for facial bone augmentation. These products are sold to surgeons specializing in skull and facial bone procedures. The firm’s focus on proprietary bioceramic technologies differentiates its offerings in the medical device market, targeting healthcare professionals who require advanced solutions for bone healing challenges. OssDsign AB’s business model centers on selling implantable medical devices developed using its unique bioceramic technologies. The company’s main customers are neurosurgeons, craniofacial surgeons, and maxillofacial surgeons who use Craniomosaic and facial bone augmentation implants during surgical operations. Revenue is derived from the direct sale of these products to medical professionals for clinical applications in bone healing and reconstruction. OssDsign is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OssDsign stock

EBIT per Share of OssDsign is -0.44 SEK in 2025.

EBIT per Share of OssDsign changed from -0.51 SEK to -0.44 SEK, representing a -13.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share OssDsign since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — OssDsign

All Key Metrics — OssDsign